Epidemiological Monitoring of COVID-19 Patients Hospitalized on Reunion Island

NCT ID: NCT05413694

Last Updated: 2022-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The island of Reunion, a French overseas department of 860,000 inhabitants, located in the Indian Ocean (OI) zone, recorded its first case of COVID-19 on March 11, 2020. The epidemic, which was described as not very severe during the year 2020 in Reunion was much more intense and more deadly in 2021, with the arrival of the new variants (South African and Indian) and exploded at the beginning of the year 2022 (variant Omicron).

Reunion has a specific island context both climato-geographically and demographically. Indeed, this French island located in the southern hemisphere in the middle of the Indian Ocean (OI) has a tropical climate and a multi-ethnic population, younger than in mainland France (16% are over 60 years old). It is also marked by a higher prevalence in the general population of certain risk factors, such as obesity (11%) and type 2 diabetes (\>10%), recognized as factors favoring severe clinical forms of COVID-19. as well as "persistent COVID-19".

This study will allow the constitution of a large-scale French cohort located in a closed overseas territory to provide answers to local specificities and to the management of the epidemic in the territory.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

telephone interview 24 months after hospitalization for Covid-19

telephone interview 24 months after hospitalization for Covid-19

Group Type EXPERIMENTAL

telephone interview 24 months after hospitalization for Covid-19

Intervention Type OTHER

telephone interview 24 months after hospitalization for Covid-19

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

telephone interview 24 months after hospitalization for Covid-19

telephone interview 24 months after hospitalization for Covid-19

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over 18 years old
* having been hospitalized at the University Hospital Center (CHU) of Reunion (minimum of one night in the hospital)
* with a positive diagnosis of COVID-19 (positive RT(reverse transcription)-PCR(Polymerase Chain Reaction) SARS-CoV-2 on a nasopharyngeal swab or positive serology or confirmed diagnosis in the medical file)
* registered in the COVIDEPI database
* whose telephone numbers are available in the computerized patient file
* residing on the island of Reunion
* knowing how to understand and speak French

Exclusion Criteria

* deceased
* opposing the use of their data
* deprived of liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or curators
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de la Réunion

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de la Réunion

Saint-Pierre, , Reunion

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Reunion

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lucie AUZANNEAU

Role: CONTACT

0262359949 ext. +262

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lucie AUZANNEAU

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022/CHU/04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.